Status: Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.
Participants needed: 800
Trial details
Phase: Phase 3Age: Up to 21Biological sex: AllType: InterventionalSponsor: Gustave Roussy, Cancer Campus, Grand ParisUpdated: Jun 26, 2025Locations: 142
Eligibility criteria
at diagnosis before the beginning of chemotherapy or [+9]
- Stage M neuroblastoma above 365 days of age at diagnosis, any MYCN status, EXC... [+51]